The National Institutes of Health announced last week that it was entering the first-ever global clinical trial of an injectable HIV-prevention drug

Receive the latest national-international updates in your inbox

The Truvada pill is taken daily to prevent HIV and has been touted as a miracle drug responsible for lowering rates of the virus across the United States. But soon, the daily pill may be overshadowed by an even simpler method — a single flu shot-like injection at the doctor's office, once every two months, NBC News reported.

The National Institutes of Health announced last week that it was entering the first-ever global clinical trial of an injectable HIV-prevention drug called cabotegravir. The trial is taking place in eight countries across three world regions — the Americas, Africa and Asia — and researchers are enrolling 4,500 gay and bisexual men along with transgender women, pulling from groups with the highest rates of new infections.

"The annual number of new HIV infections among young people, especially young men who have sex with men and transgender women who have sex with men, has been on the rise despite nearly flat HIV incidence among adults worldwide," said Raphael J. Landovitz, the protocol chair for the study.